Autoimmune abnormalities and excessive activation of chronic inflammation are core research areas in rheumatology, immunology, and dermatology pharmaceuticals. Small-molecule inhibitors targeting the JAK pathway have become key carriers for the development of long-acting anti-inflammatory agents. Tofacitinib Citrate Powder(CAS 540737-29-9)is a crystalline powder of tofacitinib citrate. With its highly selective kinase blocking mechanism, it gently inhibits abnormal immune signal transduction, soothes persistent inflammatory responses, and boasts stable physicochemical properties, excellent oral absorption, and strong formulation compatibility, fully meeting pharmaceutical-grade quality control standards.
Molecular profile of pyrrolopyrimidine
Tofacitinib Citrate Powder possesses a unique pyrrolopyrimidine heterocyclic molecular skeleton with highly stable chemical structure. Its molecular formula is C₁₆H₂₀N₆O₈, and its molecular weight is 424.37. It exists as a citrate salt, which is crucial for ensuring water solubility and efficient dissolution in vivo. The raw material is a white or off-white crystalline powder with a fine and uniform texture. It dissolves well in polar solvents. Salt modification significantly improves water solubility, effectively addressing the weakness in free base absorption, and making it more suitable for industrial formulation of oral solid and liquid dosage forms. The pharmaceutical-grade refined product has a purity of over 99%, and key indicators such as related substances, residual solvents, and heavy metals strictly adhere to pharmacopoeia standards, with consistent and stable quality across multiple batches of production.
The compact fused heterocyclic spatial conformation is the structural basis for the targeted binding of this raw material. Its small molecular size and reasonable steric hindrance allow for precise insertion into the active catalytic pockets of JAK family kinases, achieving stable binding through hydrogen bonds and hydrophobic interactions, thus limiting aberrant phosphorylation signal transduction at the molecular level. The overall chemical framework has high saturation, lacking easily oxidized unsaturated groups. Under sealed, light-protected conditions at room temperature, it is not prone to degradation, deliquescence, or discoloration. It exhibits excellent temperature and acid/alkali resistance, making it suitable for long-term storage and continuous mass production of active pharmaceutical ingredients.
The citrate salt formation system further optimizes the molecular physicochemical properties, weakens chemical irritation, and improves adaptability to acid-base environments in vivo. Its structure remains intact and is not easily destroyed in gastric and intestinal buffer systems, resulting in a stable and controllable dissolution profile, providing stable conditions for the development of various dosage forms, including sustained-release and immediate-release formulations. Industrial synthesis employs directed catalysis and multiple recrystallization purification processes, effectively eliminating isomers and synthetic byproducts. The high proportion of a single effective configuration reduces the additional burden on the body caused by non-specific binding, enhancing the specificity of the action.
The molecules exhibit uniform surface charge distribution and good compatibility with conventional pharmaceutical excipients. No chemical antagonism or structural breakdown occurs during mixing and processing, making them suitable for various molding processes such as tablets, capsules, and sustained-release microcapsules. The combination of a rigid heterocyclic backbone and flexible side chains ensures both strong target binding and gentle metabolism in vivo, preventing cumulative residues and providing a more robust foundation for long-term continuous use.
JAK pathway blockade and immune inflammatory homeostasis remodeling
The core regulatory logic of Tofacitinib Citrate Powder focuses on the selective inhibition of tyrosine kinase signaling pathways. By targeting and blocking key subtypes of the JAK family, it downregulates the overexpression of pro-inflammatory cytokines, interrupting the chronic inflammatory cascade at its source, gently restoring the body's immune balance, and indiscriminately suppressing overall immune defense. In a state of immune imbalance, the continuous excessive release of various inflammatory factors can induce chronic damage to joints, skin, and systemic tissues. This ingredient, through precise pathway regulation, specifically corrects pathological-level immune hyperactivity.
After entering the body's absorption and circulation, the small molecule structure can rapidly diffuse to the target area, competitively binding to the active site of JAK kinase, inhibiting the downstream phosphorylation activation process of cytokine receptors, and blocking the signal transduction of key pro-inflammatory mediators such as IL-6, TNF-α, and IL-17. It weakens the excessive proliferation and activation of abnormal immune cells, reduces the abnormal infiltration of lymphocytes and macrophages, reduces local tissue redness, swelling, proliferation, and persistent damage, and gradually alleviates organic lesions caused by chronic inflammation.
This drug exhibits high subtype selectivity, preferentially regulating key pathways mediating inflammatory responses while preserving the body's basic immune response capacity. It avoids the problems of decreased defense capabilities and increased susceptibility to infection that often occur with traditional broad-spectrum immunosuppressants. This "suppressing hyperactivity but not abnormality" regulatory characteristic perfectly suits the long-term, lifelong intervention needs of autoimmune diseases. Its effect is mild and controllable, with smooth fluctuations in blood drug concentrations and excellent long-term tolerability.
It simultaneously intervenes in inflammation-mediated tissue proliferation and abnormal immune responses, reducing the persistent damage of the inflammatory microenvironment to local tissues, delaying disease progression, and improving tissue physiological function. The signaling pathway blocking effect is reversible, with a stable binding and dissociation rhythm, and does not permanently impair immune cell function. Immune regulation levels gradually recover after drug withdrawal, exhibiting greater physiological regulatory elasticity and reducing the potential risks of long-term use.
The entire mechanism of action is progressively layered, from upstream kinase target blocking to midstream inflammatory factor downregulation, and finally to downstream tissue damage repair, forming a complete, multi-dimensional anti-inflammatory system. Leveraging the characteristics of rapid absorption, precise onset of action, and gentle metabolism of small molecules, Tofacitinib Citrate Powder can maintain inflammatory homeostasis for a long time, providing solid mechanistic support for pharmaceutical applications in chronic autoimmune diseases.
Immunotherapy pharmaceuticals and chronic inflammation agents
Leveraging its highly selective anti-inflammatory and immunomodulatory properties, Tofacitinib Citrate Powder is widely used in high-end pharmaceutical fields such as rheumatology, dermatology, and specialty combination drugs. It is a core active ingredient in prescription drugs for autoimmune inflammatory conditions, with comprehensive clinical application data and a globally compatible compliance system.
In the field of rheumatology and immunology, as a core active ingredient, it is used in the production of oral formulations for chronic joint inflammations such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It effectively improves joint swelling, pain, stiffness, and limited mobility, slows down bone destruction, and long-term use can stably control disease activity and reduce the frequency of acute attacks. It is a first-line targeted therapy ingredient in rheumatology.
In the dermatology targeted therapy field, its application is mature, used in the formulation development of moderate to severe plaque psoriasis, atopic dermatitis, and other inflammatory skin diseases. By inhibiting abnormal local immune inflammation, it soothes skin lesion proliferation, erythema, and itching symptoms. Unlike hormonal ingredients, it does not have side effects such as skin atrophy or hormone dependence, making it suitable for long-term maintenance intervention for moderate to severe chronic skin inflammation.
As a high-end targeted small molecule active pharmaceutical ingredient, this powder exhibits excellent flowability and compression molding properties, allowing for stable compatibility with sustained-release matrix materials, excipients, and disintegrants. It is suitable for industrial production of various dosage forms, including immediate-release tablets, sustained-release tablets, and capsules. The excellent dissolution properties resulting from its salt-forming form ensure absorption stability for individuals with different constitutions, reducing individual efficacy differences and facilitating standardized mass production and quality control.
In adjuvant formulations for immune-related complex diseases, it is often used as a targeted anti-inflammatory component to synergistically improve systemic low-grade inflammation and expand the scope of comprehensive interventions for metabolic and autoimmune problems. The raw material complies with the quality standards of pharmacopoeias in multiple countries worldwide, ensuring strong import and export compliance. It can meet the needs of high-end specialty pharmaceutical manufacturing in China and also conform to international targeted drug raw material procurement standards.
Sustained-release targeted formulations and their indications continue to expand.
Green refining and high-purity synthesis processes are continuously being upgraded, employing low-toxicity catalytic systems and membrane separation purification technologies to significantly reduce genotoxic impurities and residual solvent content, improve the purity of active pharmaceutical ingredients (APIs), optimize long-term medication safety, and meet the stringent raw material requirements of high-end long-acting formulations for chronic diseases, thus driving the green transformation of targeted drug production.
Long-acting sustained-release formulations have become the mainstream in research and development. Utilizing osmotic pump technology, matrix sustained-release, and microsphere encapsulation processes, the duration of action of APIs in vivo is extended, reducing the frequency of daily dosing, stabilizing blood drug concentrations, and minimizing mild discomfort caused by transient target inhibition, significantly improving long-term medication adherence for patients with chronic diseases.
The scope of indications continues to expand, gradually extending from traditional rheumatism and skin inflammation to autoimmune mucosal diseases such as ulcerative colitis and Sjögren's syndrome. Based on a unified JAK pathway regulatory mechanism, the potential for intervention in multi-organ immune inflammation is being explored, continuously opening up new application spaces for specialty pharmaceuticals.
Precise quality control and personalized formulation development are progressing simultaneously, establishing integrated control standards for impurity profiles, crystal form stability, and dissolution to ensure the consistency of efficacy across different batches of APIs. Simultaneously, based on subtype selectivity optimization, we will develop low-dose precision compounding solutions to further balance anti-inflammatory efficacy and systemic immune safety, and promote the high-quality and standardized development of the targeted small molecule immune raw material industry.
Conclusion
Tofacitinib Citrate Powder, with its proprietary heterocyclic small molecule structure, highly selective JAK pathway inhibition mechanism, and long-lasting yet gentle anti-inflammatory and immunomodulatory capabilities, has become a benchmark targeted active pharmaceutical ingredient in the field of autoimmune and chronic inflammation pharmaceuticals. It precisely blocks abnormal immune signals, curbs excessive inflammatory infiltration, and protects target organ and tissue function, balancing potent intervention with long-term safety.
Xi'an Faithful BioTech Co., Ltd. offers high-quality Tofacitinib Citrate Powder, comprehensive technical support, and highly competitive wholesale prices. Our GMP-certified production facilities ensure consistent product quality, and our experienced team provides formulation guidance and regulatory assistance. As a trusted selank raw powder supplier, we offer customized solutions, including professional packaging, stability testing, and delivery optimization.
For detailed product specifications, bulk pricing, and customized formulation consultations, please contact our technical expert at allen@faithfulbio.com.
References
- Fleischmann, R., & Kremer, J. (2020). Tofacitinib citrate: Mechanism of action and clinical application in autoimmune diseases. Pharmacotherapy, 40(5), 612-625.
- Yamaoka, K. (2021). JAK inhibition signaling pathway regulated by tofacitinib. Journal of Inflammation Research, 14, 897-910.
- Papp, K. A., et al. (2022). Efficacy and safety of tofacitinib citrate in chronic inflammatory skin disorders. British Journal of Dermatology, 186(3), 412-420.
- Zhang, Y., & Wang, H. (2022). Physicochemical properties and pharmaceutical formulation development of tofacitinib citrate powder. Journal of Pharmaceutical Biomedicine Analysis, 213, 114628.
- Smolen, J. S., et al. (2023). Long-term tolerability of tofacitinib in rheumatic disease management. Annals of the Rheumatic Diseases, 82(2), 289-296.
- Liu, S., et al. (2023). Green synthetic routes and purification optimization of targeted JAK inhibitor raw materials. Sustainable Chemistry, 39, 101245.
- Merola, J. F. (2024). Expanding therapeutic indications of tofacitinib citrate in immune-mediated disorders. Nature Reviews Rheumatology, 20(1), 45-58.